{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T06:00:28Z","timestamp":1775196028189,"version":"3.50.1"},"publisher-location":"New York, NY","reference-count":54,"publisher":"Springer US","isbn-type":[{"value":"9781071617519","type":"print"},{"value":"9781071617526","type":"electronic"}],"license":[{"start":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T00:00:00Z","timestamp":1636675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T00:00:00Z","timestamp":1636675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1007\/978-1-0716-1752-6_28","type":"book-chapter","created":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T21:02:28Z","timestamp":1636664548000},"page":"447-457","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Novel Brain-Penetrating Single Chain Antibodies Directed Against 3RTau for the Treatment of Alzheimer\u2019s Disease and Related Dementias"],"prefix":"10.1007","author":[{"given":"Brian","family":"Spencer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Rissman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cassia","family":"Overk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliezer","family":"Masliah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,12]]},"reference":[{"key":"28_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nrn.2015.1","volume":"17","author":"Y Wang","year":"2016","unstructured":"Wang Y, Mandelkow E (2016) Tau in physiology and pathology. Nat Rev Neurosci 17:5\u201321","journal-title":"Nat Rev Neurosci"},{"key":"28_CR2","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/nrn2194","volume":"8","author":"C Ballatore","year":"2007","unstructured":"Ballatore C, Lee VM, Trojanowski JQ (2007) Tau-mediated neurodegeneration in Alzheimer\u2019s disease and related disorders. Nat Rev Neurosci 8:663\u2013672","journal-title":"Nat Rev Neurosci"},{"key":"28_CR3","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1146\/annurev.neuro.24.1.1121","volume":"24","author":"VM Lee","year":"2001","unstructured":"Lee VM, Goedert M, Trojanowski JQ (2001) Neurodegenerative tauopathies. Annu Rev Neurosci 24:1121\u20131159","journal-title":"Annu Rev Neurosci"},{"issue":"3","key":"28_CR4","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2174\/1567205014666170417111859","volume":"15","author":"Y Gao","year":"2017","unstructured":"Gao Y, Tan L, Yu JT, Tan L (2017) Tau in Alzheimer\u2019s disease: mechanisms and therapeutic strategies. Curr Alzheimer Res 15(3):283\u2013300","journal-title":"Curr Alzheimer Res"},{"key":"28_CR5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrm2101","volume":"8","author":"C Haass","year":"2007","unstructured":"Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer\u2019s amyloid beta-peptide. Nat Rev Mol Cell Biol 8:101\u2013112","journal-title":"Nat Rev Mol Cell Biol"},{"key":"28_CR6","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.cell.2015.12.056","volume":"164","author":"B De Strooper","year":"2016","unstructured":"De Strooper B, Karran E (2016) The cellular phase of Alzheimer\u2019s disease. Cell 164:603\u2013615","journal-title":"Cell"},{"key":"28_CR7","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.1016\/j.jalz.2014.04.011","volume":"10","author":"L Sibener","year":"2014","unstructured":"Sibener L, Zaganjor I, Snyder HM, Bain LJ, Egge R et al (2014) Alzheimer\u2019s disease prevalence, costs, and prevention for military personnel and veterans. Alzheimers Dement 10:S105\u2013S110","journal-title":"Alzheimers Dement"},{"key":"28_CR8","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3233\/JAD-2005-8301","volume":"8","author":"A d C Alonso","year":"2005","unstructured":"Alonso A d C, Iqbal K (2005) Tau-induced neurodegeneration: a clue to its mechanism. J Alzheimers Dis 8:223\u2013226","journal-title":"J Alzheimers Dis"},{"key":"28_CR9","doi-asserted-by":"publisher","first-page":"10626","DOI":"10.1021\/bi00158a027","volume":"31","author":"A Andreadis","year":"1992","unstructured":"Andreadis A, Brown WM, Kosik KS (1992) Structure and novel exons of the human tau gene. Biochemistry 31:10626\u201310633","journal-title":"Biochemistry"},{"key":"28_CR10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13024-015-0025-8","volume":"10","author":"ML Caillet-Boudin","year":"2015","unstructured":"Caillet-Boudin ML, Buee L, Sergeant N, Lefebvre B (2015) Regulation of human MAPT gene expression. Mol Neurodegener 10:28","journal-title":"Mol Neurodegener"},{"key":"28_CR11","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00401-017-1707-9","volume":"133","author":"T Guo","year":"2017","unstructured":"Guo T, Noble W, Hanger DP (2017) Roles of tau protein in health and disease. Acta Neuropathol 133:665\u2013704","journal-title":"Acta Neuropathol"},{"key":"28_CR12","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.ncl.2017.01.008","volume":"35","author":"NT Olney","year":"2017","unstructured":"Olney NT, Spina S, Miller BL (2017) Frontotemporal Dementia. Neurol Clin 35:339\u2013374","journal-title":"Neurol Clin"},{"key":"28_CR13","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.brainresbull.2016.08.018","volume":"126","author":"T Arendt","year":"2016","unstructured":"Arendt T, Stieler JT, Holzer M (2016) Tau and tauopathies. Brain Res Bull 126:238\u2013292","journal-title":"Brain Res Bull"},{"key":"28_CR14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1159\/000440840","volume":"16","author":"P Tacik","year":"2016","unstructured":"Tacik P, Sanchez-Contreras M, Rademakers R, Dickson DW, Wszolek ZK (2016) Genetic disorders with tau pathology: a review of the literature and report of two patients with Tauopathy and positive family histories. Neurodegener Dis 16:12\u201321","journal-title":"Neurodegener Dis"},{"key":"28_CR15","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1007\/s12031-011-9589-0","volume":"45","author":"DW Dickson","year":"2011","unstructured":"Dickson DW, Kouri N, Murray ME, Josephs KA (2011) Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau). J Mol Neurosci 45:384\u2013389","journal-title":"J Mol Neurosci"},{"key":"28_CR16","first-page":"179","volume-title":"Alzheimer disease","author":"R Terry","year":"1994","unstructured":"Terry R, Hansen L, Masliah E (1994) Structural basis of the cognitive alterations in Alzheimer disease. In: Terry R, Katzman R (eds) Alzheimer disease. Raven Press, New York, pp 179\u2013196"},{"key":"28_CR17","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.bcp.2014.01.015","volume":"88","author":"CR Overk","year":"2014","unstructured":"Overk CR, Masliah E (2014) Pathogenesis of synaptic degeneration in Alzheimer\u2019s disease and Lewy body disease. Biochem Pharmacol 88:508\u2013516","journal-title":"Biochem Pharmacol"},{"key":"28_CR18","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol Med 8:595\u2013608","journal-title":"EMBO Mol Med"},{"key":"28_CR19","doi-asserted-by":"publisher","first-page":"a006338","DOI":"10.1101\/cshperspect.a006338","volume":"2","author":"L Mucke","year":"2012","unstructured":"Mucke L, Selkoe DJ (2012) Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med 2:a006338","journal-title":"Cold Spring Harb Perspect Med"},{"key":"28_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/nan.12208","volume":"41","author":"GG Kovacs","year":"2015","unstructured":"Kovacs GG (2015) Invited review: neuropathology of tauopathies: principles and practice. Neuropathol Appl Neurobiol 41:3\u201323","journal-title":"Neuropathol Appl Neurobiol"},{"key":"28_CR21","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/978-1-4614-0653-2_23","volume":"724","author":"N Takeda","year":"2012","unstructured":"Takeda N, Kishimoto Y, Yokota O (2012) Pick\u2019s disease. Adv Exp Med Biol 724:300\u2013316","journal-title":"Adv Exp Med Biol"},{"key":"28_CR22","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1042\/BST20120134","volume":"40","author":"SM Ward","year":"2012","unstructured":"Ward SM, Himmelstein DS, Lancia JK, Binder LI (2012) Tau oligomers and tau toxicity in neurodegenerative disease. Biochem Soc Trans 40:667\u2013671","journal-title":"Biochem Soc Trans"},{"key":"28_CR23","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1111\/ejn.12229","volume":"37","author":"NV Mohamed","year":"2013","unstructured":"Mohamed NV, Herrou T, Plouffe V, Piperno N, Leclerc N (2013) Spreading of tau pathology in Alzheimer\u2019s disease by cell-to-cell transmission. Eur J Neurosci 37:1939\u20131948","journal-title":"Eur J Neurosci"},{"key":"28_CR24","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1001\/jamaneurol.2018.2505","volume":"76","author":"GS Gibbons","year":"2019","unstructured":"Gibbons GS, Lee VMY, Trojanowski JQ (2019) Mechanisms of cell-to-cell transmission of pathological tau: a review. JAMA Neurol 76:101\u2013108","journal-title":"JAMA Neurol"},{"key":"28_CR25","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.neuint.2010.12.023","volume":"58","author":"L Martin","year":"2011","unstructured":"Martin L, Latypova X, Terro F (2011) Post-translational modifications of tau protein: implications for Alzheimer\u2019s disease. Neurochem Int 58:458\u2013471","journal-title":"Neurochem Int"},{"key":"28_CR26","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/nn.4067","volume":"18","author":"M Morris","year":"2015","unstructured":"Morris M, Knudsen GM, Maeda S, Trinidad JC, Ioanoviciu A et al (2015) Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice. Nat Neurosci 18:1183\u20131189","journal-title":"Nat Neurosci"},{"key":"28_CR27","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.bbadis.2004.07.002","volume":"1739","author":"SC Feinstein","year":"2005","unstructured":"Feinstein SC, Wilson L (2005) Inability of tau to properly regulate neuronal microtubule dynamics: a loss-of-function mechanism by which tau might mediate neuronal cell death. Biochim Biophys Acta 1739:268\u2013279","journal-title":"Biochim Biophys Acta"},{"key":"28_CR28","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.molmed.2015.03.003","volume":"21","author":"JT Pedersen","year":"2015","unstructured":"Pedersen JT, Sigurdsson EM (2015) Tau immunotherapy for Alzheimer\u2019s disease. Trends Mol Med 21:394\u2013402","journal-title":"Trends Mol Med"},{"key":"28_CR29","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s13311-015-0397-z","volume":"13","author":"E Valera","year":"2016","unstructured":"Valera E, Spencer B, Masliah E (2016) Immunotherapeutic approaches targeting amyloid-beta, alpha-Synuclein, and tau for the treatment of neurodegenerative disorders. Neurotherapeutics 13:179\u2013189","journal-title":"Neurotherapeutics"},{"key":"28_CR30","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1002\/bit.24795","volume":"110","author":"RJ Boado","year":"2013","unstructured":"Boado RJ, Lu JZ, Hui EK, Sumbria RK, Pardridge WM (2013) Pharmacokinetics and brain uptake in the rhesus monkey of a fusion protein of arylsulfatase a and a monoclonal antibody against the human insulin receptor. Biotechnol Bioeng 110:1456\u20131465","journal-title":"Biotechnol Bioeng"},{"key":"28_CR31","doi-asserted-by":"publisher","first-page":"17917","DOI":"10.1074\/jbc.M114.557439","volume":"289","author":"B Spencer","year":"2014","unstructured":"Spencer B, Verma I, Desplats P, Morvinski D, Rockenstein E et al (2014) A neuroprotective brain-penetrating endopeptidase fusion protein ameliorates Alzheimer disease pathology and restores neurogenesis. J Biol Chem 289:17917\u201317931","journal-title":"J Biol Chem"},{"key":"28_CR32","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.neurobiolaging.2014.12.002","volume":"36","author":"H Tian","year":"2015","unstructured":"Tian H, Davidowitz E, Lopez P, He P, Schulz P et al (2015) Isolation and characterization of antibody fragments selective for toxic oligomeric tau. Neurobiol Aging 36:1342\u20131355","journal-title":"Neurobiol Aging"},{"key":"28_CR33","doi-asserted-by":"publisher","first-page":"104619","DOI":"10.1016\/j.nbd.2019.104619","volume":"134","author":"A Messer","year":"2020","unstructured":"Messer A, Butler DC (2020) Optimizing intracellular antibodies (intrabodies\/nanobodies) to treat neurodegenerative disorders. Neurobiol Dis 134:104619","journal-title":"Neurobiol Dis"},{"key":"28_CR34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00401-018-1869-0","volume":"136","author":"B Spencer","year":"2018","unstructured":"Spencer B, Bruschweiler S, Sealey-Cardona M, Rockenstein E, Adame A et al (2018) Selective targeting of 3 repeat tau with brain penetrating single chain antibodies for the treatment of neurodegenerative disorders. Acta Neuropathol 136:69\u201387","journal-title":"Acta Neuropathol"},{"key":"28_CR35","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1146\/annurev.nutr.19.1.141","volume":"19","author":"MM Hussain","year":"1999","unstructured":"Hussain MM, Strickland DK, Bakillah A (1999) The mammalian low-density lipoprotein receptor family. Annu Rev Nutr 19:141\u2013172","journal-title":"Annu Rev Nutr"},{"key":"28_CR36","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0169-409X(00)00139-3","volume":"46","author":"U Bickel","year":"2001","unstructured":"Bickel U, Yoshikawa T, Pardridge WM (2001) Delivery of peptides and proteins through the blood-brain barrier. Adv Drug Deliv Rev 46:247\u2013279","journal-title":"Adv Drug Deliv Rev"},{"key":"28_CR37","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1038\/mt.2014.129","volume":"22","author":"B Spencer","year":"2014","unstructured":"Spencer B, Emadi S, Desplats P, Eleuteri S, Michael S et al (2014) ESCRT-mediated uptake and degradation of brain-targeted alpha-synuclein single chain antibody attenuates neuronal degeneration in vivo. Mol Ther 22:1753\u20131767","journal-title":"Mol Ther"},{"key":"28_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016575","volume":"6","author":"B Spencer","year":"2011","unstructured":"Spencer B, Marr RA, Gindi R, Potkar R, Michael S et al (2011) Peripheral delivery of a CNS targeted, metalo-protease reduces abeta toxicity in a mouse model of Alzheimer\u2019s disease. PLoS One 6:e16575","journal-title":"PLoS One"},{"key":"28_CR39","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1074\/jbc.M115.678185","volume":"291","author":"B Spencer","year":"2016","unstructured":"Spencer B, Potkar R, Metcalf J, Thrin I, Adame A et al (2016) Systemic central nervous system (CNS)-targeted delivery of neuropeptide Y (NPY) reduces neurodegeneration and increases neural precursor cell proliferation in a mouse model of Alzheimer disease. J Biol Chem 291:1905\u20131920","journal-title":"J Biol Chem"},{"key":"28_CR40","doi-asserted-by":"publisher","first-page":"7594","DOI":"10.1073\/pnas.0702170104","volume":"104","author":"BJ Spencer","year":"2007","unstructured":"Spencer BJ, Verma IM (2007) Targeted delivery of proteins across the blood-brain barrier. Proc Natl Acad Sci U S A 104:7594\u20137599","journal-title":"Proc Natl Acad Sci U S A"},{"key":"28_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121570","volume":"10","author":"E Rockenstein","year":"2015","unstructured":"Rockenstein E, Overk CR, Ubhi K, Mante M, Patrick C et al (2015) A novel triple repeat mutant tau transgenic model that mimics aspects of Pick\u2019s disease and Fronto-temporal Tauopathies. PLoS One 10:e0121570","journal-title":"PLoS One"},{"key":"28_CR42","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/mt.2012.66","volume":"21","author":"B Spencer","year":"2013","unstructured":"Spencer B, Michael S, Shen J, Kosberg K, Rockenstein E et al (2013) Lentivirus mediated delivery of neurosin promotes clearance of wild-type alpha-synuclein and reduces the pathology in an alpha-synuclein model of LBD. Mol Ther 21:31\u201341","journal-title":"Mol Ther"},{"key":"28_CR43","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/323346a0","volume":"323","author":"NH Jones","year":"1986","unstructured":"Jones NH, Clabby ML, Dialynas DP, Huang HJ, Herzenberg LA et al (1986) Isolation of complementary DNA clones encoding the human lymphocyte glycoprotein T1\/Leu-1. Nature 323:346\u2013349","journal-title":"Nature"},{"key":"28_CR44","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/978-1-4939-2806-4_21","volume":"1324","author":"E Masliah","year":"2015","unstructured":"Masliah E, Spencer B (2015) Applications of ApoB LDLR-binding domain approach for the development of CNS-penetrating peptides for Alzheimer\u2019s disease. Methods Mol Biol 1324:331\u2013337","journal-title":"Methods Mol Biol"},{"key":"28_CR45","volume-title":"Compositions targeting 3-repeat tau for the treatment of neurodegenerative disorders, and methods for making and using them","author":"E Masliah","year":"2017","unstructured":"Masliah E, Spencer B, Rockenstein E (2017) Compositions targeting 3-repeat tau for the treatment of neurodegenerative disorders, and methods for making and using them. WIPO, USA, New York"},{"key":"28_CR46","doi-asserted-by":"publisher","first-page":"7971","DOI":"10.1523\/JNEUROSCI.0775-16.2016","volume":"36","author":"B Spencer","year":"2016","unstructured":"Spencer B, Desplats PA, Overk CR, Valera-Martin E, Rissman RA et al (2016) Reducing endogenous alpha-Synuclein mitigates the degeneration of selective neuronal populations in an Alzheimer\u2019s disease transgenic mouse model. J Neurosci 36:7971\u20137984","journal-title":"J Neurosci"},{"key":"28_CR47","doi-asserted-by":"publisher","first-page":"13578","DOI":"10.1523\/JNEUROSCI.4390-09.2009","volume":"29","author":"B Spencer","year":"2009","unstructured":"Spencer B, Potkar R, Trejo M, Rockenstein E, Patrick C et al (2009) Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson\u2019s and Lewy body diseases. J Neurosci 29:13578\u201313588","journal-title":"J Neurosci"},{"key":"28_CR48","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1126\/science.287.5456.1265","volume":"287","author":"E Masliah","year":"2000","unstructured":"Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M et al (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287:1265\u20131269","journal-title":"Science"},{"key":"28_CR49","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1093\/brain\/awx052","volume":"140","author":"RM Nisbet","year":"2017","unstructured":"Nisbet RM, Van der Jeugd A, Leinenga G, Evans HT, Janowicz PW et al (2017) Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model. Brain 140:1220\u20131230","journal-title":"Brain"},{"key":"28_CR50","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1021\/acschemneuro.9b00217","volume":"10","author":"E Dupre","year":"2019","unstructured":"Dupre E, Danis C, Arrial A, Hanoulle X, Homa M et al (2019) Single domain antibody fragments as new tools for the detection of neuronal tau protein in cells and in mice studies. ACS Chem Neurosci 10:3997\u20134006","journal-title":"ACS Chem Neurosci"},{"key":"28_CR51","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.neurobiolaging.2020.04.014","volume":"94","author":"L Venkataraman","year":"2020","unstructured":"Venkataraman L, He P, Schulz P, Sierks MR (2020) Isolation and characterization of antibody fragment selective for human Alzheimer\u2019s disease brain-derived tau variants. Neurobiol Aging 94:7\u201314","journal-title":"Neurobiol Aging"},{"key":"28_CR52","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s40478-018-0585-2","volume":"6","author":"F Vitale","year":"2018","unstructured":"Vitale F, Giliberto L, Ruiz S, Steslow K, Marambaud P et al (2018) Anti-tau conformational scFv MC1 antibody efficiently reduces pathological tau species in adult JNPL3 mice. Acta Neuropathol Commun 6:82","journal-title":"Acta Neuropathol Commun"},{"key":"28_CR53","doi-asserted-by":"publisher","first-page":"104770","DOI":"10.1016\/j.nbd.2020.104770","volume":"137","author":"S Krishnaswamy","year":"2020","unstructured":"Krishnaswamy S, Huang HW, Marchal IS, Ryoo HD, Sigurdsson EM (2020) Neuronally expressed anti-tau scFv prevents tauopathy-induced phenotypes in drosophila models. Neurobiol Dis 137:104770","journal-title":"Neurobiol Dis"},{"key":"28_CR54","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13024-015-0043-6","volume":"10","author":"B Spencer","year":"2015","unstructured":"Spencer B, Valera E, Rockenstein E, Trejo-Morales M, Adame A et al (2015) A brain-targeted, modified neurosin (kallikrein-6) reduces alpha-synuclein accumulation in a mouse model of multiple system atrophy. Mol Neurodegener 10:48","journal-title":"Mol Neurodegener"}],"container-title":["Methods in Molecular Biology","Cell Penetrating Peptides"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-1752-6_28","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T00:17:49Z","timestamp":1666484269000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-1752-6_28"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,12]]},"ISBN":["9781071617519","9781071617526"],"references-count":54,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-1752-6_28","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,12]]},"assertion":[{"value":"12 November 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}